Nishino Masami, Egami Yasuyuki, Kawanami Shodai, Sugae Hiroki, Ukita Kohei, Kawamura Akito, Nakamura Hitoshi, Yasumoto Koji, Tsuda Masaki, Okamoto Naotaka, Matsunaga-Lee Yasuharu, Yano Masamichi, Tanouchi Jun, Yamada Takahisa, Yasumura Yoshio, Seo Masahiro, Tamaki Shunsuke, Hayashi Takaharu, Nakagawa Akito, Nakagawa Yusuke, Sotomi Yohei, Nakatani Daisaku, Hikoso Shungo, Sakata Yasushi
Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka 591-8025, Japan.
Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-ku, Sakai, Osaka 591-8025, Japan.
Int J Cardiol. 2023 May 1;378:55-63. doi: 10.1016/j.ijcard.2023.02.021. Epub 2023 Feb 14.
Drug treatments of heart failure with preserved ejection fraction (HFpEF) have a little clinical benefit, but cardiovascular polypharmacy (CP) trend is observed in elderly HFpEF. We investigated the impact of CP on octogenarian with HFpEF.
We examined 783 consecutive octogenarians (≥80 years) enrolled in the PURSUIT-HFpEF registry. We defined medications for hypertension, dyslipidemia, heart failure (HF), coronary artery disease, stroke, peripheral artery disease, and atrial fibrillation as cardiovascular medications (CM). In this study, we defined CP as ≥5 CM. We investigated whether CP was correlated with the composite end point (CE) of all-cause mortality and HF rehospitalization.
The proportion with CP was 51.9% (n = 406). Background characteristics correlated with CP were frailty, history of coronary artery disease, atrial fibrillation and left atrial dimension. Multivariable Cox proportional hazards analysis showed CP was significantly and independently correlated with CE (hazard ratio (HR): 1.31; 95% confidence Interval (CI): 1.01-1.70) in addition to age, clinical frailty scale, history of HF admission and N-terminal pro brain natriuretic peptide. Kaplan-Meier curve analysis showed that, compared with the non-CP group, the CP group had significantly higher risk of CE and HF (HR: 1.27; 95%CI: 1.04-1.56; P = 0.02 and HR: 1.46; 95%CI: 1.13-1.88; P < 0.01, respectively), but not any-cause death. In addition, diuretics were correlated with CE (HR: 1.61; 95%CI: 1.17-2.22; P < 0.01), but antithrombotic drugs and HFpEF medications were not.
CP at discharge is a prognostic factor driven by HF rehospitalization in octogenarians with HFpEF. In these patients, diuretics may be correlated with the prognosis.
射血分数保留的心力衰竭(HFpEF)的药物治疗临床获益甚微,但在老年HFpEF患者中观察到心血管药物联合使用(CP)的趋势。我们研究了CP对八旬HFpEF患者的影响。
我们检查了连续纳入PURSUIT-HFpEF注册研究的783例八旬老人(≥80岁)。我们将用于高血压、血脂异常、心力衰竭(HF)、冠状动脉疾病、中风、外周动脉疾病和心房颤动的药物定义为心血管药物(CM)。在本研究中,我们将CP定义为≥5种CM。我们研究了CP是否与全因死亡率和HF再住院的复合终点(CE)相关。
CP患者的比例为51.9%(n = 406)。与CP相关的背景特征为衰弱、冠状动脉疾病史、心房颤动和左心房内径。多变量Cox比例风险分析显示,除年龄、临床衰弱量表、HF住院史和N末端脑钠肽前体之外,CP与CE显著且独立相关(风险比(HR):1.31;95%置信区间(CI):1.01 - 1.70)。Kaplan-Meier曲线分析显示,与非CP组相比,CP组发生CE和HF的风险显著更高(HR:1.27;95%CI:1.04 - 1.56;P = 0.02和HR:1.46;95%CI:1.13 - 1.88;P < 0.01),但与任何原因的死亡无关。此外,利尿剂与CE相关(HR:1.61;95%CI:1.17 - 2.22;P < 0.01),但抗血栓药物和HFpEF药物与CE无关。
出院时的CP是八旬HFpEF患者HF再住院驱动的一个预后因素。在这些患者中,利尿剂可能与预后相关。